Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - neisseria meningitidis group c strain c11 capsular polysaccharide tetanus toxoid conjugate; haemophilus influenzae type b polysaccharide tetanus toxoid conjugate - powder and solvent for solution for injection

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - diphtheria toxoid; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; human poliovirus type 3 inactivated; haemophilus influenzae type b polysaccharide protein conjugate - powder and suspension for suspension for injection

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi pasteur europe s.a. - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid - powder and solvent for solution for injection - 10 µg/0,5 ml - haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid - hemophilus influenzae b, purified antigen conjugated

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid 10 /0,5 35 µg/dose (of wich 10 µg polysaccharide haemophilus influenzae type b and about 25 µg tetanus toxine (tt)) - powder and solvent for solution for injection - 10 µg/0.5 ml - haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid - hemophilus influenzae b, purified antigen conjugated

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid 12,5 ; neisseria meningitidis group c polysaccharides conjugated to tetanus toxoid as a carrier 5 - powder and solvent for solution for injection - haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid; neisseria meningitidis c, polysaccharides conjugated to tetanus toxoid as a carrier - hemophilus influenzae b, combinations with pertussis and toxoids

Spojené státy - angličtina - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (unii: 63gd90pp8x) (bordetella pertussis pertactin antigen - unii:63gd90pp8x), bordetella pertussis fimbriae 2/3 antigen (unii: 1o0600285a) (bordetella pertussis fimbriae 2/3 antigen - unii:1o0600285a), poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - pentacel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to haemophilus influenzae type b. pentacel is approved for use as a four dose series in children 6 weeks through 4 years of age (prior to fifth birthday). a severe allergic reaction (eg, anaphylaxis) after a previous dose of pentacel or any other diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, inactivated poliovirus vaccine or h. influenzae type b vaccine, or any ingredient of this vaccine is a contraindication to administration of pentacel [see description (11) ]. encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including pentacel. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy is a contraindication to administration of any pertussis-containing vaccine including pentacel. pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized. the safety and effectiveness of pentacel was established in the age group 6 weeks through 18 months on the basis of clinical studies [see clinical trials experience (6.1) and clinical studies (14) ]. the safety and effectiveness of pentacel in the age group 19 months through 4 years is supported by evidence in children 6 weeks through 18 months. the safety and effectiveness of pentacel in infants less than 6 weeks of age and in children 5 to 16 years of age have not been established.

Singapur - angličtina - HSA (Health Sciences Authority)

premier diagnostics pte. ltd. - immunology - purified dna of haemophilus influenzae to be used to control in vitro diagnosis techniques based in nucleic acids amplification.

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kernfarm b.v. - haemophilus parasuis (inactivated) ; erysipelothrix rhusiopathiae (inactivated) - emulsion for injection - erysipelothrix rhusiopathiae, inactivated; haemophilus parasuis, inactivated - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - pig